RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization.

ABSTRACT: The respiratory syncytial virus (RSV) is one major cause of lower respiratory tract infections in childhood and an effective vaccine is still not available. We previously described a new rhabdoviral vector vaccine, VSV-GP, a variant of the vesicular stomatitis virus (VSV), where the VSV glycoprotein G is exchanged by the glycoprotein GP of the lymphocytic choriomeningitis virus. Here, we evaluated VSV-GP as vaccine vector for RSV with the aim to induce RSV neutralizing antibodies. Wild-type F (F_wt) or a codon optimized version (F_syn) were introduced at position 5 into the VSV-GP genome. Both F versions were efficiently expressed in VSV-GP-F infected cells and incorporated into VSV-GP particles. In mice, high titers of RSV neutralizing antibodies were induced already a

SUBMITTER: Wilmschen S 

PROVIDER: S-EPMC6790003 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature